Clinical-stage biotech Alzheon has completed a $100 million Series E financing round to advance the development and commercialization of its oral drug for Alzheimer’s disease. The drug, called ALZ-801 (valiltramiprosate), is designed to inhibit the formation of soluble toxic beta amyloid oligomers, which are implicated in the cognitive decline observed in Alzheimer’s patients. The small molecule acts upstream of other late-stage amyloid-targeting treatments, offering a potentially more effective intervention by addressing the early formation of neurotoxic aggregates.
The new funding will be used to complete the current APOLLOE4 Phase 3 study to evaluate the efficacy and safety of ALZ-801 in patients with early Alzheimer’s disease. It will also support Alzheon’s plans to submit a New Drug Application (NDA) in 2024 based on the study’s outcomes, as well as preparing the manufacturing processes and commercial launch of ALZ-801, which is potentially the first oral disease-modifying therapy for Alzheimer’s.
“This latest fundraising ensures that we will have sufficient capital to complete our pivotal Phase 3 program and prepare commercialization of oral ALZ-801/valiltramiprosate with runway well into 2026,” said Ken Mace, CFO of Alzheon. “ALZ-801 has the potential to disrupt the Alzheimer’s treatment paradigm by slowing the progression of this relentless and debilitating disease, and the results from our pivotal APOLLOE4 Phase 3 trial will set the stage for the potential NDA filing this year, followed by the U.S. commercial launch in 2025.”
The pivotal APOLLOE4 Phase 3 study particularly targets patients with two copies of the APOE4/4 gene, a high-risk group that constitutes approximately 15% of Alzheimer’s patients, including actor Chris Hemsworth. The study, which has screened over 6,000 patients and enrolled 325 subjects, will conclude in the third quarter of 2024. Positive results could pave the way for regulatory approval and subsequent commercialization.
“We are at the dawn of a new era in the treatment of Alzheimer’s disease, and our novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients,” said Dr Martin Tolar, CEO of Alzheon. “Our well-differentiated drug candidate with a favorable safety profile, showing no increased risk of vasogenic brain edema in more than 3,000 AD patients, is positioned to potentially become the first oral disease modifying therapy for the treatment of Alzheimer’s disease.”
In addition to the Phase 3 study, ALZ-801 has been evaluated in a two-year Phase 2 biomarker trial involving 84 patients, including 31 APOE4/4 homozygotes. This trial, completed in late 2023, is currently in a fourth-year extension phase. The study’s primary goal is to assess the effects of ALZ-801 on biomarkers of Alzheimer’s pathology, alongside its clinical efficacy, safety, tolerability, and pharmacokinetic profile over 208 weeks of treatment.
Alzheon envisions extending the use of ALZ-801 beyond APOE4/4 homozygotes to include patients with one copy of the APOE4 gene and even noncarriers. The company says it is also focusing on a future precision medicine approach, leveraging individual genetic and biomarker information to tailor therapies that offer the greatest benefit to specific patient subsets.
The funding round, which was led by Alerce Medical Technology Partners, follows a $50 million Series D round completed in 2022.
“At Alerce, we focus on investing in companies in the late stages of development that are developing lifesaving drugs or devices with the potential to benefit millions of patient lives,” said Muneer Satter, Managing Partner of Alerce. “Alzheon’s ALZ-801 provides an innovative precision-medicine solution in an emerging Alzheimer’s pipeline with a path to potential approval in 2025.”
News
AI Struggles with Abstract Thought: Study Reveals GPT-4’s Limits
While GPT-4 performs well in structured reasoning tasks, a new study shows that its ability to adapt to variations is weak—suggesting AI still lacks true abstract understanding and flexibility in decision-making. Artificial Intelligence (AI), [...]
Turning Off Nerve Signals: Scientists Develop Promising New Pancreatic Cancer Treatment
Pancreatic cancer reprograms nerve cells to fuel its growth, but blocking these connections can shrink tumors and boost treatment effectiveness. Pancreatic cancer is closely linked to the nervous system, according to researchers from the [...]
New human antibody shows promise for Ebola virus treatment
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics. [...]
Early Alzheimer’s Detection Test – Years Before Symptoms Appear
A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving early Alzheimer’s diagnosis. Unlike amyloid-beta, tau neurofibrillary tangles are directly linked to cognitive decline. Years [...]
New mpox variant can spread rapidly across borders
International researchers, including from DTU National Food Institute, warn that the ongoing mpox outbreak in the Democratic Republic of the Congo (DRC) has the potential to spread across borders more rapidly. The mpox virus [...]
How far would you trust AI to make important decisions?
From tailored Netflix recommendations to personalized Facebook feeds, artificial intelligence (AI) adeptly serves content that matches our preferences and past behaviors. But while a restaurant tip or two is handy, how comfortable would you [...]
Can AI Really Think? Research Reveals Gaps in Logical Execution
While AI models can break down problems into structured steps, new research reveals they still fail at basic arithmetic and fact-checking—raising questions about their true reasoning abilities. Large Language Models (LLMs) have become indispensable [...]
Scientists Just Made Cancer Radiation Therapy Smarter, Safer, and More Precise
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation while sparing healthy tissues. By using a KRAS-targeting drug to mark cancer cells and attaching a radioactive [...]
Superbugs Are Losing to Science, Light, and a Little Spice
Texas A&M researchers have found that curcumin, when activated by light, can weaken antibiotic-resistant bacteria, restoring the effectiveness of conventional antibiotics. Curcumin: A Surprising Ally Against Superbugs In 2017, a woman admitted to a [...]
New Research Shatters the Perfect Pitch Myth
For decades, people believed absolute pitch was an exclusive ability granted only to those with the right genetics or early music training. But new research from the University of Surrey proves otherwise. It’s been [...]
Why Some Drinkers Suffer Devastating Liver Damage While Others Don’t
A study from Keck Medicine of USC found that heavy drinkers with diabetes, high blood pressure, or a large waistline are up to 2.4 times more likely to develop advanced liver disease. These conditions may amplify [...]
“Good” Cholesterol Could Be Bad for Your Eyes – New Study Raises Concerns
‘Good’ cholesterol may be linked to an increased risk of glaucoma in individuals over 55, while, paradoxically, ‘bad’ cholesterol may be associated with a lower risk. These findings challenge conventional beliefs about factors that [...]
Reawakening Dormant Nerve Cells: Groundbreaking Neurotechnology Restores Motor Function
A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and improving movement. In a pilot clinical trial, three patients who received spinal cord stimulation for one [...]
AI’s Energy Crisis Solved? A Revolutionary Magnetic Chip Could Change Everything
AI is evolving at an incredible pace, but its growing energy demands pose a major challenge. Enter spintronic devices—new technology that mimics the brain’s efficiency by integrating memory and processing. Scientists in Japan have [...]
Nanotechnology for oil spill response and cleanup in coastal regions
(Nanowerk News) Cleaning up after a major oil spill is a long, expensive process, and the damage to a coastal region’s ecosystem can be significant. This is especially true for the world’s Arctic region, [...]
The Role of Nanotechnology in Space Exploration
Nanotechnology, which involves working with materials at the atomic or molecular level, is becoming increasingly important in space exploration. By improving strength, thermal stability, electrical conductivity, and radiation resistance, nanotechnology is helping create lighter, more [...]
